Cargando…

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)

OBJECTIVES: Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3. This phase 3 trial assessed the efficacy and safety of tenapanor 50 mg b.i.d. for the treatment of patients with constipation-predominant irritable bow...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chey, William D., Lembo, Anthony J., Rosenbaum, David P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2020
Materias:	ARTICLE
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771640/ https://www.ncbi.nlm.nih.gov/pubmed/31934897 http://dx.doi.org/10.14309/ajg.0000000000000516

Ejemplares similares

Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2)
por: Chey, William D., et al.
Publicado: (2021)

Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
por: Chey, William D, et al.
Publicado: (2017)

Tenapanor in the Treatment of Irritable Bowel Syndrome with Constipation: Discovery, Efficacy, and Role in Management
por: Herekar, Anam, et al.
Publicado: (2023)

Emerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation
por: Eswaran, Shanti, et al.
Publicado: (2014)

Safety and tolerability of rifaximin for the treatment of irritable bowel syndrome without constipation: a pooled analysis of randomised, double‐blind, placebo‐controlled trials
por: Schoenfeld, P., et al.
Publicado: (2014)

The Role of Food in the Treatment of Bowel Disorders: Focus on Irritable Bowel Syndrome and Functional Constipation
por: Singh, Prashant, et al.
Publicado: (2022)

A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
por: Rao, Satish, et al.
Publicado: (2012)

Lower and Upper Gastrointestinal Symptoms Differ Between Individuals With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
por: Shah, Eric D, et al.
Publicado: (2018)

Effect of Food Intake on the Pharmacodynamics of Tenapanor: A Phase 1 Study
por: Johansson, Susanne A., et al.
Publicado: (2017)

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers
por: Rosenbaum, David P., et al.
Publicado: (2018)

Pelvic Floor Symptom Related Distress in Chronic Constipation Correlates With a Diagnosis of Irritable Bowel Syndrome With Constipation and Constipation Severity but Not Pelvic Floor Dyssynergia
por: Singh, Prashant, et al.
Publicado: (2019)

Effects of the vibrating capsule on colonic circadian rhythm and bowel symptoms in chronic idiopathic constipation
por: Rao, Satish S. C., et al.
Publicado: (2020)

Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
por: Schoenfeld, Philip, et al.
Publicado: (2018)

Pharmacologic, Dietary, and Psychological Treatments for Irritable Bowel Syndrome With Constipation: Cost Utility Analysis
por: Shah, Eric D., et al.
Publicado: (2021)

The Spectrum of Constipation-Predominant Irritable Bowel Syndrome and Chronic Idiopathic Constipation: US Survey Assessing Symptoms, Care Seeking, and Disease Burden
por: Heidelbaugh, Joel J, et al.
Publicado: (2015)

Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation
por: Chang, L., et al.
Publicado: (2016)

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation
por: Yiannakou, Yan, et al.
Publicado: (2018)

Randomised clinical trial: minesapride vs placebo for irritable bowel syndrome with predominant constipation
por: Hamatani, Tatsuto, et al.
Publicado: (2020)

A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
por: Johansson, Susanne, et al.
Publicado: (2016)

Functional constipation masked as irritable bowel syndrome
por: Tosto, Monica, et al.
Publicado: (2020)

Randomized Trial of 2 Delayed-Release Formulations of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
por: Chey, William D., et al.
Publicado: (2021)

Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation
por: Patel, Sarah, et al.
Publicado: (2021)

The gut microbiome and irritable bowel syndrome
por: Menees, Stacy, et al.
Publicado: (2018)

Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
por: Johansson, Susanne, et al.
Publicado: (2017)

Constipation-Predominant Irritable Bowel Syndrome Associated to Hyperprolactinemia
por: Seretis, C., et al.
Publicado: (2011)

Optimal management of constipation associated with irritable bowel syndrome
por: Furnari, Manuele, et al.
Publicado: (2015)

Irritable bowel syndrome and diet
por: Portincasa, Piero, et al.
Publicado: (2017)

Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
por: Kaptchuk, Ted J., et al.
Publicado: (2010)

Tenapanor administration and the activity of the H(+)‐coupled transporter PepT1 in healthy volunteers
por: Johansson, Susanne, et al.
Publicado: (2017)

Lubiprostone for the Treatment of Adult Women with Irritable Bowel Syndrome with Constipation
por: Soubra, Mahmoud, et al.
Publicado: (2012)

Review article: linaclotide for the management of irritable bowel syndrome with constipation
por: Layer, P, et al.
Publicado: (2014)

Plecanatide Improves Symptoms of Irritable Bowel Syndrome with Constipation: Results of an Integrated Efficacy and Safety Analysis of Two Phase 3 Trials
por: Brenner, Darren M, et al.
Publicado: (2023)

Early response predicts a sustained response to eluxadoline in patients with irritable bowel syndrome with diarrhoea in two Phase 3 studies
por: Chey, W. D., et al.
Publicado: (2017)

White Matter Microstructural Similarity and Diversity of Functional Constipation and Constipation-predominant Irritable Bowel Syndrome
por: Nan, Jiaofen, et al.
Publicado: (2018)

The NHE3 Inhibitor Tenapanor Prevents Intestinal Obstructions in CFTR-Deleted Mice
por: Tan, Xinjie, et al.
Publicado: (2022)

Polyethylene Glycol 3350 in the Treatment of Chronic Idiopathic Constipation: Post hoc Analysis Using FDA Endpoints
por: Menees, Stacy B., et al.
Publicado: (2022)

Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome
por: Fodor, Anthony A., et al.
Publicado: (2018)

Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial
por: Lacy, Brian E., et al.
Publicado: (2022)

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
por: Shah, Eric D., et al.
Publicado: (2021)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vbtveeo72sbr0jis0v3086jhk1